Saniona to Present Preclinical Data on SAN903 at the ASPET Annual Meeting at Experimental Biology 2021
April 14, 2021
Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced that its research team will present preclinical data on SAN903 in a model of idiopathic pulmonary fibrosis at the American Society of Pharmacology and Experimental Therapeutics (ASPET) Annual Meeting at Experimental Biology (EB) 2021, which is being held virtually between April 27 and 30, 2021.
SAN903 is a novel, potential first-in-class medicine based on inhibition of the calcium-activated potassium ion channel, KCa3.1. This ion channel is found in immune cells and fibroblasts, and it controls the proliferation, migration and release of cytokines and collagen. Previous studies have indicated that KCa3.1 inhibition may reduce inflammation and fibrosis in various diseases. Saniona is currently evaluating SAN903 in preclinical models of multiple rare inflammatory and fibrotic disorders and expects to initiate Phase 1 clinical trials in the first half of 2022.
At the ASPET conference, Saniona will present a poster titled, “Comparison of KCa3.1 Inhibitor, SAN903, with Nintedanib and Pirfenidone in an Idiopathic Pulmonary Fibrosis Model.” The abstract (L5029) is available on the meeting website and the poster is also available online to registered attendees from April 13 to May 31, 2021. Saniona also plans to share its SAN903 preclinical data in additional scientific and investor forums in the future.
“SAN903 was discovered in Saniona’s labs and provides an excellent example of the potential of our proprietary ion channel drug discovery engine to yield new treatments for rare diseases,” said Jørgen Drejer, Chief Scientific Officer of Saniona. “We have previously demonstrated in multiple preclinical models the ability of SAN903 to selectively target and completely inhibit KCa3.1, and the new data we are presenting at ASPET further strengthen our confidence in this molecule as a potential treatment for rare inflammatory and fibrotic disorders.”
For more information, please contact
Trista Morrison, Chief Communications Officer, Saniona. Office: + 1 (781) 810-9227. Email: email@example.com
The information was submitted for publication, through the agency of the contact person set out above, at 14:00 CEST on 14 April 2021.
Saniona is a biopharmaceutical company focused on discovering, developing, and delivering innovative treatments for rare disease patients around the world. The company’s lead product candidate, Tesomet, is in mid-stage clinical trials for hypothalamic obesity and Prader-Willi syndrome, severe rare disorders characterized by uncontrollable hunger and intractable weight gain. Saniona’s robust drug discovery engine has generated a library now consisting of more than 20,000 proprietary modulators of ion channels, a significantly untapped drug class that is scientifically validated. Lead candidate SAN711 is entering Phase 1 for rare neuropathic disorders, with SAN903 for rare inflammatory and fibrotic disorders advancing through preclinical studies. Led by an experienced scientific and operational team, Saniona has an established research organization in Copenhagen, Denmark and is building its corporate office in the Boston, Massachusetts area, U.S. The company’s shares are listed on Nasdaq Stockholm Small Cap (OMX: SANION). Read more at www.saniona.com.
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Equinor ASA: Generalforsamlingen vedtok utbytte på USD 0,12 per aksje for fjerde kvartal 202011.5.2021 20:32:22 CEST | Pressemelding
Generalforsamlingen i Equinor ASA (OSE: EQNR, NYSE: EQNR) godkjente 11. mai 2021 styrets forslag til årsregnskap og årsberetning for Equinor ASA for 2020. Årsregnskap og årsberetning for Equinor ASA og for konsernet for 2020 ble godkjent, og det utdeles et utbytte på 0,12 amerikanske dollar per aksje for fjerde kvartal 2020. Utbyttet for fjerde kvartal 2020 tilfaller aksjeeiere som er registrert i Equinors aksjeeierregister i verdipapirsentralen (VPS) per utløpet av 14. mai 2021 (”Eierregisterdatoen”). Forutsatt ordinært oppgjør i VPS innebærer dette at man må være aksjeeier per 11. mai 2021 for å ha rett til utbytte. Utbytte til rettighetshavere under ADR-programmet (American Depository Receipts) i USA tilfaller også rettighetshavere per 11. mai 2021. Aksjene vil bli handlet eks. utbytte på Oslo Børs fra og med 12. mai 2021. På New York Stock Exchange vil ADR’er bli handlet eks. utbytte fra og med 13. mai 2021. Aksjeeiere med aksjer som handles på Oslo Børs vil motta sitt utbytte i no
Equinor ASA: Annual general meeting approved dividend of USD 0.12 per share for fourth quarter 202011.5.2021 20:32:22 CEST | Press release
On 11 May 2021, the annual general meeting (AGM) of shareholders in Equinor ASA (OSE: EQNR, NYSE: EQNR) approved the annual report and accounts for Equinor ASA for 2020, as proposed by the board of directors. The annual accounts and the annual report for Equinor ASA and the Equinor group for 2020 were approved, and a dividend of US dollar (”USD”) 0.12 per share will be distributed for the fourth quarter of 2020. The fourth quarter 2020 dividend accrues to the shareholders as registered in Equinor’s shareholder register with the Norwegian Central Securities Depository (VPS) as of expiry of 14 May 2021 (the ”Record Date”). Subject to ordinary settlement in VPS, this implies that the right to dividend accrues to shareholders as of 11 May 2021. For US ADR (American Depository Receipts) holders, dividend accrues also as of 11 May 2021. The shares will be traded ex-dividend on the Oslo Stock Exchange (Oslo Børs) from and including 12 May 2021. On New York Stock Exchange, the ADRs will trade
Kommuniké från årsstämma i Corline Biomedical AB (publ)11.5.2021 19:47:30 CEST | Pressemelding
Idag den 11 maj 2021 hölls årsstämma i Corline Biomedical AB (publ). Nedan följer en sammanfattning av de beslut som fattades. Samtliga beslut fattades enhälligt. Fastställande av resultat Bolagsstämman fastställde resultat- och balansräkningarna och beslutade, i enlighet med styrelsens förslag, att resultatet enligt den fastställda resultaträkningen skulle överföras i ny räkning. Någon utdelning lämnas inte. Ansvarsfrihet Bolagsstämman beviljade styrelseledamöterna och verkställande direktören ansvarsfrihet för förvaltningen av Bolagets angelägenheter under räkenskapsåret 2020. Något beslut fattades emellertid inte avseende styrelseordföranden, då han – som enda röstande på bolagsstämman – inte kunde rösta om den egna ansvarsfriheten. Fastställande av antalet styrelseledamöter, styrelsesuppleanter och antalet revisorer Stämman beslutade att styrelsen ska bestå av fem (5) styrelseledamöter samt en (1) styrelsesuppleant. Vidare beslutades att bolaget ska fortsätta ha ett registrerat rev
TGS-NOPEC Geophysical Company ASA (TGS) - Annual General Meeting Held11.5.2021 18:44:31 CEST | Press release
OSLO, Norway (11 May 2021) - The Annual General Meeting of TGS was held on 11 May 2021. All resolutions proposed were approved by the shareholders. The minutes from the Annual General Meeting are attached to this announcement. About TGS TGS provides scientific data and intelligence to companies active in the energy sector. In addition to a global, extensive and diverse energy data library, TGS offers specialized services such as advanced processing and analytics alongside cloud-based data applications and solutions. Forward Looking Statement All statements in this press release other than statements of historical fact are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that are difficult to predict, and are based upon assumptions as to future events that may not prove accurate. These factors include TGS' reliance on a cyclical industry and principal customers, TGS' ability to continue to expand markets for licensing of data, and TGS' ab
Banque Profil de Gestion SA : Changement d’actionnaire de référence, nouvelle raison sociale et changements au sein du Conseil d’administration11.5.2021 18:21:13 CEST | Press release
Communiqué de presse Banque Profil de Gestion SA : Changement d’actionnaire de référence, nouvelle raison sociale et changements au sein du Conseil d’administration Genève, le 11 mai 2021 – Comme annoncé le 9 février dernier, Banque Profil de Gestion SA (BPDG), son actionnaire actuel de référence (Banca Profilo S.p.A) ainsi que les actionnaires de la société One Swiss Bank SA (OSB) ont signé deux contrats de vente d’actions formalisant, d’une part, le rachat par BPDG de 100% du capital de OSB et, d’autre part, la cession par Banca Profilo SpA des 60.4% d’actions qu’elle détient dans BPDG aux actionnaires actuels de OSB (la «Transaction»). La Transaction impliquera également la fusion subséquente par absorption de OSB par BPDG. Pour rappel, la Transaction est notamment soumise à agrément de la FINMA. Les démarches y relatives sont en cours et l’exécution des deux contrats de vente formalisant la Transaction (le «Closing ») interviendra le 1er juin prochain, sauf objection de la FINMA d’
Brunel AGM 202111.5.2021 18:00:00 CEST | Press release
Amsterdam, 11 May 2021 – Brunel International N.V. (Brunel; BRNL), a global provider of flexible workforce solutions and expertise, today announced the voting results of the Annual General Meeting of Shareholders (AGM) of 11 May 2021. The AGM approved all voting items that were on the agenda. As a result, Jilko Andringa is reappointed as a member of the board of directors for a new term of four years. At the close of the meeting Mr Aat Schouwenaar, chairman of the supervisory board, retired from the supervisory board after having served on the supervisory board for 20 years. Mr Just Spee is reappointed as a member of the Supervisory Board for his second term of four years and will succeed Mr Aat Schouwenaar as chair of the Supervisory Board. Mr Frank van der Vloed is appointed as member of the Supervisory Board for a term of four years. A dividend of €0.30 per share of €0.03 par value has been declared for the 2020 financial year. The dividend, less 15% dividend withholding tax, will b
Outcome of 2021 Shareholders’ Meeting11.5.2021 17:45:00 CEST | Press release
Outcome of 2021 Shareholders’ Meeting Brussels, May 11, 2021, 17:45 CEST - Solvay today held its General Shareholders’ Meeting virtually. Shareholders voted in favor of all the resolutions proposed. More specifically, they approved the payment of a gross dividend of €3.75 per share for the year 2020. After deduction of the interim dividend of €1.50 gross per share, paid in January 2021, the balance amounts to €2.25 gross per share (€1.575 net, after deduction of 30% of withholding tax). Calendar of payment related to the 2020 final dividend May 17, 2021: ex-date May 18, 2021: record date May 19, 2021: payment date During the meeting, shareholders approved the reelection for a four year mandate for Nicolas Boël, Ilham Kadri, Bernard de Laguiche, Françoise de Viron and Agnès Lemarchand and for a three year mandate for Hervé Coppens d'Eeckenbrugge. They also approved the appointment of two new directors, Dr. Wolfgang Colberg and Edouard Janssen, to replace Amparo Moraleda and Evelyn du Mo